EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Use of metabolic imaging to monitor heterogeneity of tumour response following therapeutic mTORC1/2 pathway inhibition

Stephanie Ling, Alex Dexter, Alan M Race, Shreya Sharma, Gregory Hamm, Urszula M Polanska, Rosetta Consortium Cancer Research UK, John F Marshall iD, Zoltan Takats, Kevin Brindle, Mariia O Yuneva, George Poulogiannis und 5 weitere

Disease Models & Mechanisms · 2025

DOI: 10.1242/dmm.050804 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Disease Models & Mechanisms, 2025. Verfasst von Stephanie Ling und 16 weiteren Autor:innen. Beteiligte Einrichtung: Imaging and Data Analytics, AstraZeneca, Cambridge CB2 0AA, UK. Hauptthemen laut MEDLINE: Mechanistic Target of Rapamycin Complex 2, Mechanistic Target of Rapamycin Complex 1, Signal Transduction, Neoplasms. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 58 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Cancer Research UK, AstraZeneca.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The PI3K–mTOR–AKT pathway regulates tumour proliferation, gene expression and metabolism, but pathway inhibition induces heterogeneous feedback reactivation, limiting anti-tumour responses. Measuring heterogeneity of pathway inhibition in tissues using protein biomarker phosphorylation or location is challenging. An integrated multi-modal imaging workflow was developed to assess the heterogeneity of AZD2014 (mTORC1/2 inhibitor) response in a PTEN-null renal cancer model. Spatial responses of metabolite biomarkers were analysed by mass spectrometry imaging (MSI). Control and treated tumours were classified according to metabolite-defined regions enriched in control versus AZD2014-treated tumours, respectively. Noticeably, AZD2014-treated tumours retained regions similar to regions dominant in untreated tumours. Imaging mass cytometry analysis of protein biomarkers in ‘control-like’ regions following AZD2014 treatment showed reduced phospho-S6, indicating suppression, but retained high expression of the glucose transporter GLUT1. Increasing PI3K–AKT inhibition by combining with AZD8186 (PI3Kβ inhibitor) further decreased the control-like metabolic signature, showing PI3K-dependent resistance. This demonstrates that MSI-based workflows yield novel insights into the pharmacodynamic effects of mTORC1/2 inhibition in tumours, which classical biomarkers do not resolve. Coupling these workflows with spatial-omics approaches can deliver greater insights into heterogeneity of treatment response.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Mechanistic Target of Rapamycin Complex 2Mechanistic Target of Rapamycin Complex 1Signal TransductionNeoplasmsAnimalsHumansCell Line, TumorPyrimidinesProto-Oncogene Proteins c-aktPhosphatidylinositol 3-KinasesMiceBiomarkers, TumorBenzamidesMorpholines

Stichwörter der Autor:innen

AKTImaging mass cytometryMass spectrometry imagingPI3KPharmacodynamicSpatial multi-omicsmTOR

Substanzen

Mechanistic Target of Rapamycin Complex 2Mechanistic Target of Rapamycin Complex 1vistusertibPyrimidinesProto-Oncogene Proteins c-aktPhosphatidylinositol 3-KinasesBiomarkers, TumorBenzamidesMorpholines

Autor:innen und Institutionen

  • Imaging and Data Analytics, AstraZeneca, Cambridge CB2 0AA, UK.
  • National Physical Laboratory, Teddington TW11 0LA, UK.
  • Early Oncology, AstraZeneca, Cambridge CB2 0AA, UK.
  • Barts Cancer Institute, London EC1M 6AU, UK.
  • Imperial College London, London SW7 2AZ, UK.
  • The Rosalind Franklin Institute, Harwell Campus, Didcot OX11 0QS, UK.

ORCID-Profile: John F Marshall, Andrew D Campbell, Simon T Barry

Förderung

  • Cancer Research UK
  • AstraZeneca

Zitieren

APA

Ling, S., Dexter, A., Race, A. M., Sharma, S., Hamm, G., Polanska, U. M., Rosetta Consortium Cancer Research UK, Marshall, J. F., Takats, Z., Brindle, K., Yuneva, M. O., Poulogiannis, G., Campbell, A. D., Sansom, O. J., Goodwin, R. J. A., Bunch, J., & Barry, S. T. (2025). Use of metabolic imaging to monitor heterogeneity of tumour response following therapeutic mTORC1/2 pathway inhibition. Disease Models & Mechanisms. https://doi.org/10.1242/dmm.050804

Vancouver

Ling S, Dexter A, Race AM, Sharma S, Hamm G, Polanska UM, et al. Use of metabolic imaging to monitor heterogeneity of tumour response following therapeutic mTORC1/2 pathway inhibition. Disease Models & Mechanisms. 2025. doi:10.1242/dmm.050804

BibTeX
@article{Ling2025,
  author = {Ling, Stephanie and Dexter, Alex and Race, Alan M and Sharma, Shreya and Hamm, Gregory and Polanska, Urszula M and Rosetta Consortium Cancer Research UK, Rosetta Consortium Cancer Research UK and Marshall, John F and Takats, Zoltan and Brindle, Kevin and Yuneva, Mariia O and Poulogiannis, George and Campbell, Andrew D and Sansom, Owen J and Goodwin, Richard J A and Bunch, Josephine and Barry, Simon T},
  title = {Use of metabolic imaging to monitor heterogeneity of tumour response following therapeutic mTORC1/2 pathway inhibition},
  journal = {Disease Models & Mechanisms},
  year = {2025},
  doi = {10.1242/dmm.050804}
}
Kostenlos starten →